Huahui Health’s Libevitug Wins NMPA Approval as World’s First HDV Antibody Therapy
CompanyDrug

Huahui Health’s Libevitug Wins NMPA Approval as World’s First HDV Antibody Therapy

CompanyDeals

GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing

CompanyDrug

AstraZeneca’s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis

CompanyDeals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

CompanyDeals

Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets

CompanyDrug

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

CompanyDrug

Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study

CompanyDrug

Eisai/Biogen’s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer’s Dosing

CompanyDeals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

CompanyDrug

Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer

CompanyDeals

Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy

CompanyDeals

Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base